Vimarsana
Biggest News Aggregation in the World

Midatech Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Midatech Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Midatech Pharma Today - Breaking & Trending Today

HDAC (Histone Deacetylase) Inhibitors Market szie to grow by USD 172.61 Milion between 2022-2027, Technavio - Vimarsana News

HDAC (Histone Deacetylase) Inhibitors Market szie to grow by USD 172.61 Milion between 2022-2027, Technavio

/PRNewswire/ -- The HDAC (histone deacetylase) Inhibitors Market by Route of Administration, Distribution Channel, and Geography - Forecast and Analysis...

Modified Release Neurology Therapeutics Report 2024 - Neurology Therapeutics Advance with Modified R - Vimarsana News

Modified Release Neurology Therapeutics Report 2024 - Neurology Therapeutics Advance with Modified R

DUBLIN--(BUSINESS WIRE)--The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.com's offering.Large pharmaceutical and biotechnology companies are increasingly pursuing in-licensing to offset lower than expected drug development productivity and surging research costs. Data mining...

Global Somatostatin Analogs Market Report 2024-2030 Featuring Major Players - Novartis, Sun Pharma, Midatech Pharma, Ipsen Pharma, Chiasma, Peptron, Dauntless Pharma, Camurus, Teva, and Pfizer - Vimarsana News

Global Somatostatin Analogs Market Report 2024-2030 Featuring Major Players - Novartis, Sun Pharma, Midatech Pharma, Ipsen Pharma, Chiasma, Peptron, Dauntless Pharma, Camurus, Teva, and Pfizer

/PRNewswire/ -- The "Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...

Global Modified Release Neurology Therapeutics Analysis 2024 - Extended Release Formulations Redefine Treatment Protocols - Vimarsana News

Global Modified Release Neurology Therapeutics Analysis 2024 - Extended Release Formulations Redefine Treatment Protocols

/PRNewswire/ -- The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.com's offering. Large pharmaceutical and...

Biodexa Pharmaceuticals (LON:MTPH) Stock Price Crosses Above Fifty Day Moving Average of $18.00 - Vimarsana News

Biodexa Pharmaceuticals (LON:MTPH) Stock Price Crosses Above Fifty Day Moving Average of $18.00

Biodexa Pharmaceuticals Plc (LON:MTPH – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 18 ($0.23) and traded as high as GBX 20 ($0.25). Biodexa Pharmaceuticals shares last traded at GBX 18 ($0.23), with a volume of […]